Fallenius A G, Askensten U G, Skoog L K, Auer G U
Cytometry. 1987 May;8(3):260-6. doi: 10.1002/cyto.990080305.
The reliability of microspectrophotometric (MSP) and flow cytometric (FCM) nuclear DNA measurements has been studied in 50 human breast adenocarcinomas. The tumor material was obtained by means of fine-needle aspiration biopsy, and all samples except one were found to be highly representative. The results confirm earlier observations that a good correlation exists between modal value (MV) determined by MSP and DNA index (DI) determined by FCM. However, when tumors were classified into low and high malignant variants according to FCM/DI, FCM/S-phase percentages, and MSP histogram types, the concordance was less pronounced. This was found to be due mainly to the fact that in near-diploid tumors a discrepancy exists between MSP and FCM ploidy, as well as between MSP distribution pattern and the estimated percentages of cells in the S-phase region. Another source of discrepancy was observed in tumors with stemlines in the normal tetraploid region, including cells with highly scattered aneuploid DNA values. These tumors were judged by MSP as aneuploid/high malignant and by FCM as euploid/low malignant. In view of this discrepancy, we conclude that the simple determination of the stemline position by MSP/MV or FCM/DI is not sufficient for adequate cytochemical malignancy grading of breast carcinomas. We suggest that a combination of ploidy and percentage of cells scattered outside the modal peaks is a more sensitive method for optimal cytochemical malignancy grading in breast carcinomas.
对50例人乳腺腺癌进行了显微分光光度法(MSP)和流式细胞术(FCM)检测细胞核DNA的可靠性研究。肿瘤组织通过细针穿刺活检获取,除1例外,所有样本均具有高度代表性。结果证实了早期的观察结果,即MSP测定的众数(MV)与FCM测定的DNA指数(DI)之间存在良好的相关性。然而,当根据FCM/DI、FCM/S期百分比和MSP直方图类型将肿瘤分为低恶性和高恶性变体时,一致性并不明显。发现这主要是由于在近二倍体肿瘤中,MSP和FCM的倍性之间存在差异,以及MSP分布模式与S期区域细胞估计百分比之间存在差异。在正常四倍体区域具有干系的肿瘤中也观察到另一个差异来源,包括具有高度分散的非整倍体DNA值的细胞。这些肿瘤通过MSP判定为非整倍体/高恶性,通过FCM判定为整倍体/低恶性。鉴于这种差异,我们得出结论,仅通过MSP/MV或FCM/DI简单确定干系位置不足以对乳腺癌进行充分的细胞化学恶性分级。我们建议,倍性和模式峰外分散细胞百分比的组合是一种更敏感的方法,用于乳腺癌最佳细胞化学恶性分级。